#United States #FDA Approval #Cranford #LYMPHIR #Citius Oncology

Citius Oncology Secures Funding for LYMPHIR® Commercialization

Citius Oncology, Inc., a prominent player in the biopharmaceutical sector focused on developing innovative oncology therapies, has successfully secured up to $36.5 million through a combination of debt and equity financing. This significant funding is earmarked to accelerate the commercialization of their recently FDA-approved therapy, LYMPHIR® (denileukin diftitox-cxdl), specifically targeting adult patients suffering from relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL).

The firm's financing strategy includes a senior secured credit facility with Avenue Capital Group amounting to $25 million, which features an initial tranche of $10 million funded immediately upon closing. Additionally, a concurrent exercise of outstanding warrants held by a healthcare-focused institutional investor is expected to raise approximately $11.5 million. Together, these financial maneuvers aim to support Citius Oncology's ongoing efforts to bring LYMPHIR to market while maintaining a strategic flexibility for future growth actions.

Financial Breakdown and Future Initiatives

The credit facility's structure allows for the release of further funds contingent on achieving predefined revenue milestones and liquidity conditions. The credit spans 3.5 years, providing a robust framework to enhance Citius Oncology's operational capabilities. These funds are essential as the company prepares to expand its sales efforts, boost market access initiatives, and fortify its manufacturing supply chain to support the ramp-up of LYMPHIR.

Leonard Mazur, Chairman and CEO of Citius Oncology, remarked on the significance of this financial support, stating, "This Credit Facility strengthens our ability to continue our momentum with the LYMPHIR launch. Our collaboration with Avenue Capital underscores their confidence in our growth trajectory and the therapeutic potential of LYMPHIR. This partnership is instrumental as we aim to increase accessibility to this vital treatment for patients who have limited options."

Chad Norman, Senior Portfolio Manager at Avenue Capital Group, expressed excitement about supporting Citius Oncology's commercialization strategy, emphasizing the unique position of LYMPHIR in the oncology landscape. With FDA approval in hand and a targeted approach to the underserved CTCL market, Citius Oncology is strategically positioned to capitalize on its first FDA-approved asset.

Understanding LYMPHIR® and Its Impact

LYMPHIR® is a targeted immune therapy designed to treat relapsed or refractory CTCL, which is a rare form of skin lymphoma. The therapy's distinctive mechanism combines the IL-2 receptor binding domain with fragments of diphtheria toxin. This fusion protein works by specifically targeting IL-2 receptors on cancerous cells, resulting in their destruction. LYMPHIR is particularly aimed at improving outcomes for patients who have already undergone systemic therapies without success.

In 2021, LEYMIA® secured regulatory approval in Japan for CTCL and peripheral T-cell lymphoma, marking a pivotal moment in its development. Citius Acquisition of this asset further amplifies their efforts to serve patients globally, excluding certain regions like India and parts of Asia. In December 2025, Citius launched LYMPHIR in the U.S., aiming to tap into an estimated market exceeding $400 million, which remains largely unmet by current therapies.

Future Prospects

Citius Oncology plans to allocate the net proceeds from this latest financial round towards critical commercialization efforts, including expanding its sales force, implementing market access strategies, and continuing necessary medical affairs activities. The company also aims to strengthen its overall corporate framework and ensure a steady supply chain to fulfill anticipated demand.

In conclusion, with robust financial backing and a clear mission to enhance patient outcomes in oncology, Citius Oncology stands poised to play a significant role in advancing therapies for challenging conditions like CTCL. As they proceed with their commercialization journey, the firm's commitment to innovation and patient care remains steadfast.